Turning cancer into a curable disease: Immunotherapy expert John Connolly picks up the reins as the new CSO of Sean Parker’s cancer institute
John Connolly synced with the folks at the Parker Institute for Cancer Immunotherapy early on.
As the science chief at Singapore-based Tessa Therapeutics, he worked on a next-gen CAR-T with an amped up package of T cells. But the same immunotherapy focus runs right through his days teaching at Baylor and on back to getting his PhD in immunology from Dartmouth Medical School, where he studied human dendritic cell biology, all of which helped make him an obvious choice as a top collaborator with the institute.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.